Great to have been at the Theranostics World Congress with the Accelerate.EU consortium.
We were happy to share the progress made on Astatine-211 and targeted alpha therapies.
#AccelerateEU #Astatine211 #Theranostics #TargetedAlphaTherapy #NuclearMedicine #IHI
Attending Theranostics World Congress? Meet members of the Accelerate.EU consortium to discuss our progress in developing Β²ΒΉΒΉAt-based alpha radiotheranostic.
π Poster presentation
βRegulatory Challenges for Novel Alpha Therapies: A Call for Harmonizationβ
Presented by Prof. Antero Abrunhosa.
Letβs connect and exchange on the future of alpha therapies.
ππ‘ππ ππ«π ππ‘π πππ―ππ§πππ ππ¬ π¨π ππ-211?
At-211 emits a single Ξ±-particle with high Linear Energy Transfer (LET) (~100 keV/Β΅m), leading to π‘π’π π‘π₯π² π₯π¨πππ₯π’π³ππ ππ§π πππππππ’π―π πππ πππ¦ππ π.
Moreover, the Ξ±-particles emitted by At-211 have a very short path length in tissue (50-100 Β΅m), ensuring that radiation is concentrated within a few cell diameters, π¦π’π§π’π¦π’π³π’π§π π¨ππ-πππ«π ππ πππππππ¬.
Learn more about the advantages of At-211 on our website: https://lnkd.in/eCysUBqv
Did you know that 1 in 6 breast cancer cases is classified as triple negative (TNBC)? This challenging subtype lacks effective therapeutic targets and leaves those affected with limited options and a dismal prognosis when metastatic.
Accelerate. EU, is pioneering an innovative approach: 211 Astatine-dual FAPi therapy. This groundbreaking treatment links a potent therapeutic isotope to a protein in the tumor microenvironment, leveraging molecular imaging and theranostics to advance care.
Let's take a moment to celebrate JΓ©rΓ΄me Harray remarkable dedication and leadership in making the Accelerate. EU project a reality!
Thank you for the countless hours and unwavering vision youβve invested to make this project possible. Weβre grateful to have you leading this initiative, paving the way for improved access to innovative #cancer treatments across Europe.
π Accelerate. EU Program Kick-Off!
We were happy to bring together 17 leading European institutions and companies from 9 countries for a highly constructive kick-off meeting of the Accelerate.EU program. By blending academic expertise with industrial innovation, this initiative is set to make a real difference in improving access to radiotheranostics and innovative #cancer treatments.
π EUR 16 Million Granted to Accelerate.EU to Advance Cancer Therapies in Europe!
It has officially launched with EUR 16 million in funding from the European Commission! Led by IBA and the Jules Bordet Institute, this project is all about making a real difference in cancer care by creating a reliable European supply chain for Astatine-211 (211At), a promising treatment for aggressive cancers.
With 17 partners across 9 countries, Accelerate.EU unites experts from academia and industry
